1 Title: COVID-19 vaccination atlas: an integrative systems vaccinology approach

2 Authors: Wasim Aluísio Prates-Syed^{1,2,16}, Dennyson Leandro Mathias da Fonseca³, Shahab Zaki Pour⁴, Lena F Schimke², Aline Lira^{1,2,16}, Nelson Cortes^{1,2,16}, Jaqueline Dinis Queiroz 3 Silva^{1,6,16}, Evelyn Carvalho^{1,6,16}, Igor Salerno Filgueiras², Tania Geraldine Churascari 4 5 Vinces⁵, Lorena C. S. Chaves⁷, Gerhard Wunderlich⁵, Ricardo Durães-Carvalho^{4,8}, Niels O. S. Câmara¹, Haroldo Dutra Dias¹², Hans D. Ochs¹¹, José E. Krieger¹⁰, Helder I Nakaya^{6,13}, 6 Otávio Cabral-Marques^{1,3,6,15,16,+}, Gustavo Cabral-Miranda^{1,2,6,16,+,*}. 7

- 8 **Emails:** wasim.syed@usp.br, dennyson@usp.br, shahab.178@gmail.com, 9 igor.filgueiras@usp.br, lenaschimke@hotmail.com, cv.tania@usp.br, aline.llira@usp.br, evelyn.carvalho@unesp.br, 10 nelson.cortes@usp.br, jaquelinedinis@gmail.com, 11 lorenacschaves@gmail.com, gwunder@usp.br, rdcarval@gmail.com, niels@icb.usp.br, 12 haroldodd@gmail.com, hans.ochs@seattlechildrens.org, sabinoec@usp.br, 13 j.krieger@hc.fm.usp.br, hnakaya@usp.br, otavio.cmarques@usp.br, gcabral.miranda@usp.br
- 14 **Affiliations:**

20

21

22

23

24

25

26

27 28

29

33

34

37

38

- 1. Department of Immunology, Institute of Biomedical Sciences (ICB), University of 15 16 São Paulo (USP), São Paulo, Brazil.
- 2. The Interunits Graduate Program in Biotechnology of the University of São Paulo, the 17 18 Butantan Institute, and the Technological Research Institute of the State of São Paulo, 19 Brazil.
 - 3. Interunit Postgraduate Program on Bioinformatics, Institute of Mathematics and Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil.
 - 4. Laboratory of Molecular Evolution and Bioinformatics, Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil;
 - 5. Department of Parasitology, Institute of Biomedical Sciences (ICB), University of São Paulo (USP), São Paulo, Brazil.
 - 6. Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
 - 7. Department of Microbiology and Immunology, School of Medicine, Emory University, Atlanta, Georgia, United States.
- 8. São Paulo School of Medicine, Department of Microbiology, Immunology and 30 31 Parasitology, and Department of Morphology and Genetics, Federal University of São 32 Paulo (UNIFESP), São Paulo, SP, Brazil.
 - 9. Department of Infectious and Parasitic Diseases, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
- 35 10. Heart Institute, Clinical Hospital, Faculty of Medicine, University of São Paulo, 36 Brazil; Laboratory of Genetics and Molecular Cardiology, Clinical Hospital, Faculty of Medicine, University of São Paulo, Brazil.
 - 11. Department of Pediatrics, University of Washington School of Medicine, and Seattle Children's Research Institute, Seattle, WA, USA.
- 40 12. Department of Neuroscience, Institute of Biomedical Sciences, Federal University of 41 Minas Gerais (UFMG), Belo Horizonte, Brazil
- 42 13. Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
- 43 14. DO'R Institute for research, São Paulo, Brazil
- 44 15. Department of Medicine, Division of Molecular Medicine, University of São Paulo School of Medicine, São Paulo, Brazil. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 45

- 46 16. Institute of Tropical Medicine, Faculty of Medicine of the University of São Paulo,
 47 Brazil
- 48 *Correspondence to: gcabral.miranda@usp.br or gcabral.miranda@gmail.com, Gustavo
- 49 Cabral-Miranda, Institute of Tropical Medicine, Faculty of Medicine of the University of São50 Paulo, Brazil
- 51 + Equal contribution as supervisor and senior author.

52 Abstract:

53 The COVID-19 vaccinations have played a significant role in controlling the pandemic. To 54 elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed 55 through an integrative systems vaccinology approach. The atlas includes both healthy 56 individuals and those infected with or without prior vaccination, and covers the administration 57 of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, 58 Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different 59 types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, 60 61 LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous 62 vaccination and infection were described, and it was also shown how a full vaccination 63 regimen markedly limited the shift of immune responses during natural infection, thereby 64 constraining disease progression. Finally, the common transcripts shared across COVID-19 65 vaccines and vaccines against other pathogens were described.

66 Main text

67 1. Introduction

68 Coronavirus Disease 2019 (COVID-19) is a respiratory disease caused by Severe 69 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with its first documented 70 outbreak in Wuhan, China, in 2019¹. The emergence of variants of concern (VOCs) urged 71 adjustments in strategies to effectively control their spread due to the heterogeneity of 72 symptoms, severity, transmission, and decreased efficacy of vaccines against new VOCs, 73 especially the Omicron variant (Chung et al., 2021; Xia et al., 2022).

74 Remarkably, it is estimated that COVID-19 vaccinations prevented more than 14 75 million deaths in only one year after global vaccination enrollment⁴. This was accomplished 76 by breakthrough innovations in vaccinology, in addition to global efforts to fund worldwide 77 clinical trials, including classical and new-generation vaccines⁵. The mRNA vaccines (RNA) 78 Comirnaty® (BNT162b2, BNT) and Spikevax® (mRNA-1273, MO), the viral vectored (VV) 79 vaccines Covishield®/Vaxzebria® (AZD1222, ChAdOx-1, ChAd) and Jcovden® (Janssen), 80 and inactivated vaccines (IN) such as Coronavac® and Covilo® (BBIBP-CORV, BBIBP) 81 were among the first and most used vaccines worldwide until 2023 ⁶. Particularly, ChAd and 82 BNT were the most used vaccines during the first years of vaccination and 2 and 3-dose 83 heterologous regimens were widely used and assessed ^{7,8}. The combination of different 84 vaccines and platforms shows how classical and new-generation vaccines can help control 85 epidemics and potentially trigger complementary systemic immune responses that individual 86 vaccine technologies are intrinsically incapable of ^{8–11}. The complete homologous vaccination regimen showed high efficacy in clinical trials against COVID-19, as high as 95.0%, 94.1%, 87 and 90% for new-generation vaccines, such as BNT, MO, and ChAd, respectively ¹¹⁻¹³. 88 89 Classical technologies, such as inactivated virus (IN), and protein subunit (SU) vaccines, have 90 also shown high efficacy and effectiveness. BBIBP and Zifivax® (ZF2001) had 78.1% and 91 75.7% efficacy against symptomatic infections, respectively ^{14,15}. Although these vaccines 92 were initially tested and approved in homologous regimens, heterologous vaccination has 93 been tested in clinical trials and real-world scenarios to address ongoing waves of infection and new VOCs 8,16. 94

95 To understand how different vaccination regimens and vaccine technologies affect the 96 immune system in healthy individuals and infected patients during, and after infection by 97 SARS-CoV-2, it was integrated RNAseq data from five distinct studies that include 98 vaccinations with Covilo®, Vaxzebria® or Covishield®, Spikevax®, Comirnaty®, and 99 Zifivax®. These studies, however, present data from different time points, populations and 100 regimens, and there is a need to obtain a unified perspective of their immunological signatures. 101 This study introduces a systems vaccinology atlas that delineates shared and individual 102 profiles across conditions in both healthy and infected individuals. The findings indicate that 103 completing a vaccination regimen can effectively limit disease progression. Additionally, it 104 demonstrates that heterologous vaccination strategies can diversify immunological signatures, 105 potentially enhancing protection against the disease. Furthermore, the study explores immune 106 responses induced by vaccines targeting other pathogens and reveals a substantial overlap in 107 genes related to the innate immune system with COVID-19 vaccines.

109 2. Results

110 Immune-related gene expression varies by vaccine type, regimen, and infection status.

111 A total of 562 samples were analyzed, sourced from peripheral blood mononuclear 112 cells (PBMCs) of 245 participants involved in five distinct studies (Table 1, Fig. 1A). These 113 participants were either vaccinated (V) with one or more of the four different types of vaccines 114 (IN, SU, RNA, and VV), which comprised both homologous (HO) and heterologous (HE) 115 vaccination regimens and were administered in one (V1), two (V2), or three doses (V3), or 116 were infected patients (I) with or without prior vaccination (Fig. 1B-C, Fig. S1-2). Many 117 issues were identified with the GSE206023 count matrix, in which most of the genes were 118 annotated in GenBank IDs with multiple identifier versions for the same genes. Moreover, 119 only 10% of these identifiers could be annotated, comprising less than 2% of the immune 120 genes, in contrast to more than 90% present in the other datasets. Given the importance of this 121 dataset regarding the diversity of vaccine technologies, a decision was made to reprocess the 122 read files in FASTQ and align it with the reference transcriptome using pseudoalignment in 123 the Kallisto package ¹⁷. While other datasets employed HISAT2, pseudoalignment was chosen 124 due to its superior speed, robustness, and lower computational resource requirements 125 compared to HISAT2.¹⁸.

126 The temporal dynamics of differentially expressed genes (DEGs) was influenced by 127 vaccine type, number of doses, and administration regimen. This happened across 128 convalescent and non-convalescent individuals, as well as infected patients with previous 129 vaccination (Fig. 2A, Fig. S3). Notably, the BNT vaccine exhibited a significant increase in 130 total DEGs across the three doses, with three DEGs six days after the first dose (BNT V1), 131 followed by 613 and 96 DEGs 1 day after the second (BNT V2) and third doses (BNT V3), 132 respectively, with a more substantial increase with two doses of BNT followed by a single 133 dose of MO (BNT-MO V3) (Fig. 2A). In contrast, it was observed that the ChAd vaccine 134 exhibited a divergent pattern compared to BNT in non-convalescent individuals, with 135 decreased up- and downregulated DEGs over the first week after two homologous doses 136 (ChAd V2), and a higher number of DEGs in the heterologous vaccinations (ChAd-BNT V2 137 and ChAd-BNT V3) (Fig. 2A, Fig. S3). A similar trend was observed in homologous and 138 heterologous vaccinations with the BBIBP vaccine after a third dose (Fig. 2A, Fig. S3). It was 139 evident that homologous vaccination with an inactivated virus vaccine does not generate 140 significant DEGs in a third dose (BBIBP V3) and thus requires heterologous vaccination with 141 a different technology, such as a SU vaccine (ZF2001 V3) (Fig. 2A, Fig. S3).

142 Furthermore, infections in vaccinated and unvaccinated patients notably affected the 143 number of downregulated DEGs (Fig. 2A, Fig. S3). Among unvaccinated infected 144 individuals, DEGs were higher in severe disease cases than in moderate cases over 51 days. 145 Conversely, in infected patients with prior complete vaccination, primarily mild and moderate 146 disease, this number was at least 10 times lower. However, infected hospitalized patients with 147 moderate and severe disease who were vaccinated with a single dose of BNT 10-11 days 148 before hospitalization, the number of DEGs was similar to that of infected patients on days 10 149 and 26. This pattern could also be influenced by the age range (71-90 years) of these patients, which is a major risk factor for COVID-19¹⁹. Of the four infected patients, three recovered, 150 151 and one died (Fig. S3). The surviving patients continued dexamethasone treatment and 152 received a second dose of the vaccine 40 days post-infection²⁰. Samples were collected 15-20 153 days post-vaccination, exhibiting more DEGs than at a later time post-vaccination in non-154 convalescent individuals with BNT or ChAd (Fig. 2A). The gene expression patterns in 155 unvaccinated and single-dose vaccinated patients during the second infection were similar,

but vaccinated individuals exhibited a notable, threefold reduction in DEGs compared to with
unvaccinated counterparts. Only in the total DEGs analysis, without discriminating by
ontology (immune and non-immune), was an apparent relationship between vaccine type,
disease severity, and time.

160 Upon filtering immune-related DEGs, it became clear that the fraction of immune-161 related genes decreased over time in vaccinees and infected patients (Fig. 2A, Fig. S3). 162 Specifically, this investigation focused solely the immune-related genes excluding genes from 163 the BCR and TCR repertoire [immunoglobulin chains (IG@) and T-cell receptors (TR@)]. 164 Particularly in infected patients, the first days showed a greater fraction of immune genes, 165 which decreased over time, whereas the number of other non-immune-related genes increased 166 (Fig. 2A, Fig. S3A). In addition, infected patients with prior complete immunization showed 167 fewer DEGs and a smaller fraction of immune genes. Nevertheless, vaccination results in the 168 activation substantially more immune genes, which follow proportionally to other genes, 169 either increasing or decreasing, depending on the vaccine type. This contrast indicates that the 170 immune response induced by vaccines is quantitatively more balanced in terms of the 171 expression of immune genes than infection. To identify patterns among these conditions, 172 immune-related and non-immune DEGs were compared distinctively (q-value < 0.10) (Fig. 173 2B, Fig. S4A). It was observed that the majority of shared genes among the different vaccine 174 types were non-immune genes, such as ANKRD22, GBP1P1, GPRB4, and HES4 (Fig. S4A-175 B). Moreover, the most shared genes, such as LRRN3, ADAMTS2, and FAM209B, were 176 more present among infected patients (Fig. 5B). This shows the role of other processes in 177 vaccination and, to a greater extent, infection.

178 To understand these non-immune processes during vaccination, the analysis focused 179 on the non-immune genes. It was found that a majority of these genes were related to 180 ubiquitous cellular and metabolic processes, and the regulation of biological processes (Fig. 181 2A-B, Fig. S4). However, the subsequent analysis specifically targeted immune genes. The 182 shared immune DEGs exhibited one central cluster associated with the groups infected for the 183 first time (vaccinated and unvaccinated) and another cluster comprising the first day of 184 vaccination with homologous or heterologous second and third doses of ChAd, BNT, and MO 185 (Fig. 2B). Notably, the number of shared genes among infected groups was 2- to 10-fold 186 higher than non-convalescent-vaccinated groups. In addition, it was observed a decrease in 187 shared DEGs between infected patients with prior vaccination (BNT-I) and infected patients 188 with prior infection and prior vaccination (I-BNT-I), in a similar proportion to non-189 convalescent vaccinated groups, which was not evident in the non-immune DEGs context 190 (Fig. 3B, Fig. S4A). This finding was also associated with vaccine type, viral vector vaccines 191 (ChAd and ChAd-BNT), and subunit vaccines (ZF2001), which were more evident with non-192 immune DEGs (Fig. S4A).

193 In contrast, there was a noticeable decrease in the number of genes on subsequent days, 194 particularly on day 7, suggesting the initiation of homeostatic processes over time. This 195 reduction in DEGs becomes more pronounced on subsequent days. However, this decrease 196 contrasts with the trend observed with increasing doses, particularly notable in homologous 197 RNA vaccines and heterologous ChAd with subsequent vaccination with BNT. This indicates 198 a broader activation of diverse genes with a higher number of doses. Particularly, vaccination 199 with BNT following one or two doses of ChAd led to a significantly greater number of total 200 DEGs compared to the two-dose homologous regimen of either vaccine (Fig. 2A-B, Fig. S4). 201 Comparing to the two doses of ChAd on day 3, there was a three-fold increase in upregulated 202 DEGs, which reduced by half on day 7. Conversely, downregulated DEGs were 13-fold higher

in the ChAd-BNT regimen but increased two-fold on day 7. Remarkably, even though the
 assessment was conducted only one day post-vaccination, upregulated DEGs exhibited in the
 ChAd-ChAd-BNT regimen were approximately two-fold higher than those with two doses of
 ChAd and 1.2-fold higher than those with BNT-MO.

In contrast, the number of up- and downregulated genes was nearly equivalent in infected individuals, regardless of prior vaccination status (**Fig. 2A, Fig. S4A**). Additionally, genes from unvaccinated infected individuals were largely constrained within their group and had a limited overlap with vaccinated individuals.

To describe the immune transcriptome of individual vaccination regimens, were compared all the genes present in the datasets with the immune system related genes (Fig. 4D). Following this comparison, the enrichment of gene sets associated with immune responses was analyzed. (Fig. 4C).

215 Limited Immunological Profile Observed with Three Homologous doses of BBIBP

216 The BBIBP exhibited enrichment of processes associated with the innate immune system, 217 including the antiviral response mediated by interferons, neutrophils, eosinophils, and 218 monocytes, which were consistently found to be negatively regulated (Fig. 4C). Further 219 analysis of gene expression within these processes and cells revealed specific genes of interest 220 (Fig. S4-7). On day 14, we identified genes associated with inflammation (NLRP9, 221 upregulated), immune regulation (IDO2), macrophage-mediated antiviral response (CCL3, 222 downregulated), neutrophil activation (CXCL8), and lymphocyte-macrophage signaling 223 (WNT4, upregulated)²¹. On day 28, a transcription factor (NFKBIA, downregulated) present 224 in ARPP and B cells, which regulate immune system processes, and CCL2 (downregulated), 225 a monocyte chemokine, were observed.

226 ZF2001 as Heterologous Booster Elicits Distinct Immune Response Profile

227 A heterologous regimen with the ZF2001 vaccine in individuals who had previously received 228 two doses of the BBIBP vaccine resulted in a distinct gene expression profile compared to the 229 homologous vaccine. Although most DEGs were upregulated, a small fraction of genes related 230 to the immune system were downregulated (Fig. 2A). On the seventh day post-vaccination, 231 there was a suppression of genes associated with inflammatory processes (IL1RN, FOSL2, 232 and CD58), antiviral response and interferons (CXCL2, CXCL3, CCL3, CCL4, CCL20, 233 BCL3, ADM, LGALS3, FAU), as well as genes related to antigen recognition and 234 presentation (TNFAIP3, FOSL1, RAB3B, and ICAM). This suppression also extended to 235 genes expressed in eosinophils (VAMP2), NK cells (RNF19B), dendritic cells (NFKBIA, 236 FOSL1), T cells (IL2), B cells, and immunoglobulin-mediated responses (BCL3, BCL6) (Fig. 237 2C, Fig. S6-9).

238 On the other hand, a predominance of upregulated genes was observed on the seventh day, 239 particularly associated with other chemokines (CX3CL1, CXCL8, CXCL14, CCL8, 240 CX3CL1), mast cells (CPLX2, CLNK, LGALS3), ARPP (ITGB8, TRIL), APCs (ADGRF5, 241 FLT1, IL33, WNT4), adaptive response processes and cells (CACNB4, EOMES, SPNS2, 242 BCAR1), as well as the complement system (Fig. S6-9). Specifically, within the complement 243 system, genes from the classical pathway (C4B and C4BPB) and lectins (MASP1 and 244 MASP2) were overexpressed (Fig. S6-9). In the adaptive immune system, there were genes related to T cell activation (IL13, EPHB1, TNFAIP8L2, TARM1), specifically Th2 response 245

(IL33), Th17 (CCR2), TCD8 (EMP2), B cell and Ig-mediated response (WNT3A) (Fig. S6-9).

248 Viral Vectored Vaccine ChAd Induces Early Gene Expression of Complement and249 Adaptive Immune Systems

Genes related to T cells and the cellular response to the viral vector were expressed as early as the third-day post-vaccination with the first dose. Notably, genes such as CCNB2 and CAV1, which play roles in the cell cycle and T cell activation, respectively, exhibited sustained expression levels up to the seventh day. Additionally, the innate immune system processes are enriched, including interferon-mediated antiviral responses, acute phase response proteins (ARPP), and NK cell, related proteins along with upregulated genes from the complement system associated with the alternative pathway (CFB and CFD) (**Fig. S7-9**).

257 It is also essential to highlight the distinct expression of genes related to humoral responses 258 on the third and seventh days (Fig. S8). These expression patterns were also observed in B-259 cell genes, with overexpression between days 3, 6, and 7, returning to the initial profile by the 260 sixth day. Conversely, except for genes associated to cellular response, B cells processes, and 261 the humoral immune response were enriched on the first day after the second dose. However, 262 gene-level analysis still revealed diverse and high gene expression at this stage, especially for 263 the cytokine CCL2 and immunoregulatory enzyme IDO1. When comparing genes related to 264 the humoral response between doses, it was noted that these genes were less expressed and 265 less diverse at the second dose. On the third day, only two DEGs associated with the humoral 266 response were identified (SYK and KIT). Particularly, on day 7, CD27, a gene involved in 267 immunoglobulin synthesis, ²² was increased after the first dose and suppressed after the second 268 dose.

269 Distinct Gene Expression Patterns Elicited by mRNA Vaccines BNT and MO

270 The mRNA vaccines BNT and MO demonstrate distinct gene expression patterns. Six days 271 after the first dose of BNT, only 3 DEGs were identified, with IFI27 being the only immune-272 related gene (Fig. 2A, Fig. S4-7). Subsequent second and third BNT doses revealed elevated 273 activation of antiviral and interferon responses, ARPP, and the function of neutrophils, 274 eosinophils, monocytes and dendritic cells (Fig. 4C). These sets were similarly enriched 275 following the third homologous vaccination, except for dendritic cells. A third heterologous 276 vaccination with MO induced dendritic cell function, inflammation, and the activation of the 277 cellular adaptive immune system. Notably, IFI27 expression was exclusive to all BNT doses 278 except for the third dose of MO (Fig. S4-7). Neutrophils shared genes in various vaccination regimens, including CCL8, CXCL9, and CCL2 (Fig. S4-7)²³. In addition, eosinophils 279 280 exhibited pronounced CCL3L1 expression following MO vaccination, which plays a pivotal 281 role in virus clearance from the lungs ²⁴.

Immune Signatures in Infected and Convalescent Patients Before and After Vaccination with BNT

To understand the impact of vaccination before and after infection, we analyzed infected and convalescent patients. We found that innate immune cells and processes were highly activated and persisted for several days, especially interferons 1 and 2, neutrophils, APCs, and bacterium-directed PRRs (TLR4 and NOD) (Fig. 4C, Fig. S4-7). Additionally, B-cell processes, including chemotaxis and homeostasis, are activated (Fig. 4C, Fig. S4-7). There was also a Th2 response in BNT-I (D26, mild), although T cell processes were predominantly 290 downregulated under other infection conditions. In a gene-level analysis, many genes related 291 to the adaptive immune system were upregulated and downregulated. Likewise, it was evident 292 that infection induced different subsets of genes compared to vaccination in every immune 293 process and cell type (Fig. S4-7). Considering the innate immune system and classical 294 pathway complement system genes (such as CR1 and C1R), high and persistent gene 295 expression, especially those associated with inflammation (e.g., IL10, HMGB2, ELANE, and 296 NLRP6), activation of neutrophils (e.g., CD177, ANXA3, and IL18RAP) and mast cells (e.g., 297 S100A12 and SLC15A4), may be associated with the initiation of cytokine storms, allergic reactions, and thrombosis ^{25,26}. Although most genes participating in adaptive immune system 298 299 processes were highly downregulated, there were also many highly expressed genes in the 300 humoral response, including genes related to Ig-mediated responses, ARPP, and other B-cell 301 processes, as well as in cellular response and T- cell processes. This pattern varied among 302 convalescent and infected patients who had received prior vaccination, regardless of whether 303 they had a completed or incomplete vaccine regimen (Fig. S4).

304 Stratification of COVID-19 vaccination and infection using multivariate analyses

305 To describe the similarities and differences among all conditions, it was conducted a 306 Principal components analysis (PCA) with all immune DEGs (Fig. 3A-D). Principal 307 component 1 (PC1) accounted for 66.8% of the variance, whereas PC2 accounted for 15.7%, 308 totaling 81.9%. PC1 was predominantly defined by genes associated with interleukin (IL) 309 signaling pathways (IL18RAP, SOS2, MAP2K6), apoptosis (HMGB2), inflammation-related 310 processes (RC3H1, ALOX5, PPARG, and FCER1A), as well as processes linked to lymphocytes (ETS1), particularly to T cells (VNN1, CD6, TESPA1, RPL22, PCLG1, TCF7, 311 312 TRAT1, and CD3G) (Fig. 3C). On the other hand, PC2 was defined by genes related to 313 antiviral and interferon responses (IFI35, IFITM3, STAT1-2, IDO1, ADAR, BST2, GBP1, 314 and PML), as well as APCs (BATF2, LILRB1) and antigen receptors, processing and 315 presentation (ARPP) (TAP2, PDIA3, TRIM26, and CTSS) (Fig. 3D).

316 The results revealed the presence of three primary clusters (Fig. 3A). The first 317 significant cluster indicated patients with ongoing infection, characterized by genes associated 318 with IL-signaling pathways, apoptosis, and inflammation-related processes in cluster 1 (C1; 319 Fig. 3A,C). While this cluster included specific individuals with previous vaccination, we did 320 not anticipate a substantial influence of vaccination, particularly considering that it was 321 administered 10 days before the onset of COVID-19 symptoms. Nevertheless, it is evident 322 that patients who received a complete vaccination regimen and were subsequently infected 323 (BNT-I), as well as a patient who received a second dose of BNT 10 days after recovery 324 (BNT-I-BNT, D51), showed overlap with Cluster 2 (C2). The C2 cluster comprises 325 homologous vaccinations for both convalescent patients and non-convalescent individuals. 326 Additionally, healthy-vaccinated individuals were part of this cluster, but it also included 327 patients with two infections (without severe outcomes) and one patient initially experiencing 328 severe disease 51 days after the onset of symptoms, who were hospitalized and treated with 329 steroids. Given that this cluster occupies the central position in the plot and represents 330 comparatively healthy conditions, the proximity of eigenvalues from the first cluster to the 331 second cluster suggests an ongoing, time-dependent homeostatic process. In contrast, the third 332 cluster (C3) consisted of homologous and heterologous vaccinations involving genetic-based 333 vaccines such as BNT, ChAd, and MO, specifically within the initial three days post-334 vaccination. This cluster is characterized by genes in PC2 and shares a minimum number of 335 certain genes with infected patients in C1. Nevertheless, the expression of the top 20 336 contributing genes in PC2 was significantly higher in C3 than in C1 conditions (Fig. 3B,D).

These differences were marked by genes such as IDO1, IL31RA, and LILRB1, which were
not expressed during infection and are associated with antimicrobial response, chemotaxis,
and MHC1 presentation, respectively.

340 Machine learning classification of COVID-19 vaccine types and infection based on 341 immune genes

342 Using the PCA results, genes in PC1 and PC2 ($\cos 2 > 0.5$) were filtered and a random 343 forest model was trained for classification based on the variable "type", including infection 344 and the different vaccine types (Fig. 4A). This model demonstrated remarkable performance, 345 with an accuracy of 91.2%, an area under the receiver-operator curve (ROC) of 0.990, and an 346 out-of-bag (OOB) error of 0.086. The main gene predictors were associated with transcriptional regulation (GATA3, ZNF3, KMT2A, and ASXL1), antiviral response 347 348 (SP100), granzyme (GZMM), ARPP (ITGAM, ACTG1, LGALS3), and T cell response 349 (STAT5B) (Fig. 4B). The high expression of the transcriptional regulation associated genes 350 GATA3, ZNF3, KMT2A, and ASXL1, an antiviral response gene (SP100), and the granzyme 351 GZMM, were key markers for infection, along with the suppression of genes that play roles 352 in ARPP (ITGAM, ACTG1, LGALS3), and T-cell response (STAT5B) SP100 was also 353 notably expressed in vaccination, in the first 3 days after the second and third doses of both 354 homologous and heterologous regimens. LGALS3 was also markedly expressed in the first 3 355 days of vaccination with ChAd. This observation aligns with the fact that viral vectored 356 vaccines, like ChAd, act through certain infection associated mechanisms to deliver genetic 357 material into the nucleus²⁷.

358 Comparative Analysis of Vaccines Against Other Pathogens

359 Understanding how COVID-19 vaccines relate to classical and consolidated vaccines 360 used in routine immunization is essential. Therefore, all immune-related DEGs associated 361 with various vaccines, including COVID-19, were compared using MSigDB Vax collection 362 ²⁸. The dataset was manually annotated and selected all up- and downregulated genes from 363 vaccination-only sets (see Methods, Fig. 1A). This approach originated from several gene 364 sets, including those correlated with antibody titers, T-cell responses, and training sets. To 365 understand the extent of gene overlap, was performed a gene-level analysis of these shared 366 genes from PBMC-derived samples, to match the COVID-19 conditions, while filtering DEGs 367 with -1 < L2FC >1 (Fig. 5A-C, Fig. S8 and 9).

368 The analysis uncovered a notable overlap of genes, both up- and downregulated, 369 between vaccines targeting viruses and bacteria based on inactivated (IN) and live-attenuated 370 (LA) pathogens and COVID-19 vaccines (Fig. 5A-C). This overlap was most prominent in 371 the initial two weeks and following the second and third doses. Specifically, downregulated 372 DEGs were predominantly associated with infection, particularly with LA vaccines (Fig. 5A). Conversely, upregulated DEGs were common among vaccinated individuals, comprising both 373 374 non-convalescent and convalescent individuals. This overlap extended to include infected 375 patients who had undergone prior one-dose vaccination.

The observations revealed two main clusters of genes, predominantly representing the innate and adaptive immune systems (**Fig. S6**). While the second cluster encompasses genes present in the adaptive immune system, these genes also exhibit a lower degree of overlap with the innate immune system. Notably, the second cluster appeared more heterogeneous and demonstrated significantly fewer shared genes across vaccines than the first cluster. In this

381 first cluster, we observed that COVID-19 vaccines and others shared most innate genes that 382 also play a role in the adaptive immune system (Fig. 5D). Some of the most common genes 383 between vaccines included chemokines and receptors (CCL2, CCL3, CCL8, CCL20, CCR1, 384 and CXCL8), interferons and antiviral responses (IRF1, IFIT1, STAT1, and STAT2), ARPP 385 (TAP1, TAP2, HLA-DMB, and HLA-DMA), and some adaptive immune system genes 386 (RIGI, FAS, CD83, BCL6, and FCER1G) (Fig. 5B). On the other hand, some of the genes 387 present mainly in COVID-19 vaccine conditions are chemokines, such as CCL2, which play 388 a diverse role in the innate, adaptive, and complement systems (Fig. 5C). CCL2 is also shared 389 with the monovalent influenza vaccine adjuvanted with AS03 and the LA vaccine Fluzone® 390 ²⁹. Although most non-COVID-19 vaccines sharing genes with COVID-19 vaccines are 391 targeted against the influenza virus, Stamaril®, a yellow fever LA vaccine, shares many innate immune system genes with COVID-19 vaccines ³⁰. Indeed, an overrepresentation analysis 392 393 (ORA, FDR < 0.25) of immune genes showed that general leukocyte processes and antiviral 394 and interferon processes were enriched in most vaccines and vaccine types (Fig. 5E). VV 395 vaccines against COVID-19 and tuberculosis (MVA85A) were significantly (qvalue < 0.10) 396 enriched with genes related to eosinophils, monocytes, and neutrophils (Fig. 5E).

397 Discussion

This COVID-19 vaccination atlas comprehensively analyzes the dynamic and diverse immune responses generated by different vaccination strategies against COVID-19. These strategies include homologous and heterologous vaccination regimens, diverse vaccine types, and consideration of prior vaccination status at the time of infection, alongside the time elapsed since infection (**Fig. 1A**).

403 The analysis reveals that immune-related genes constitute a smaller proportion of the 404 total DEGs than other biological processes, including cellular, metabolic, and regulation of 405 biological processes (Fig. 2A, Fig. S4). A limitation of this analysis by gene ontology of 406 biological process is that some genes that are not annotated as immune play ubiquitous roles 407 in cellular and metabolic processes present in immune cells. This can also be attributed to the 408 inoculation of immunogens through syringe injection, which leads to local and limited tissue 409 damage at the injection site. Indeed, intramuscular injections are prone to human errors, and 410 questions remain regarding which injection site and procedure are optimal and safest ³¹. This 411 vaccine administration issue and the molecular characteristics of different vaccine platforms 412 might explain reactogenic behavior in some individuals. In the context of infection, this 413 pattern illustrates the regulation of numerous genes influenced by viral infection cycle processes and the host response ^{32,33}. This variability is primarily attributed to diverse response 414 415 mechanisms among individuals, impacting disease progression or immunity³⁴. However, this 416 aspect will not be discussed in more details since it diverges from the primary objective of our 417 study, which focuses on describing the transcriptome of the immune system. Nonetheless, it 418 is noteworthy as it raises questions regarding non-immunological factors and their role in 419 vaccination and disease development.

420 Moreover, it was found that these DEGs are highly shared between the studied 421 conditions, encompassing both infection and vaccination conditions. In addition, a higher 422 representation of immune-related genes was observed in the vaccination group compared to 423 infection (Fig. 2A). Specifically, genes associated with inflammation, the complement 424 system, neutrophil function, antiviral responses, and interferon pathways exhibit prolonged 425 activation during infection, while adaptive immune-related genes are significantly 426 downregulated (Fig. S4-7). In contrast, vaccination triggers the activation of chemokines and 427 adaptive immune-related genes.

428 The surge in up- and downregulated DEGs in the early days after the second and third 429 doses of BNT or MO indicates the ability to activate the innate immune response. Considering 430 the rapid mRNA expression, post-inoculation might also trigger antigen-presenting cells to initiate an adaptive immune response ³⁵. Notably, despite having the same mRNA platform as 431 432 BNT and encoding the same spike amino acid sequence, the MO vaccine differs in nucleotide 433 sequence due to codon optimization and the absence of pseudouridine modification^{36,37}. 434 However, whether this substantial increase is attributable to an immune response to the third 435 dose, the technology, or other factors, such as LNP composition, remains unclear.

The heterologous vaccination regimen was also explored with different types of
vaccines, namely ChAd and BNT, and BBIBP and ZF2001. It was found that it can contribute
to the diversification of immune responses, address some of the technological limitations of
the vaccine platforms, and consequently enhance protection against COVID-19.

440 The ChAd vaccine contains a chimpanzee adenovirus viral vector that shares epitopes 441 with prevalent human adenoviruses, which can trigger an adaptive immune response against 442 the vector³⁸. It is therefore possible that the administration of multiple doses of the vaccine 443 may generates antibodies targeting the vector, potentially limiting the delivery of genetic 444 material, unlike mRNA vaccines ³⁹. Hence, heterologous vaccination is a clinical and 445 immunologically important option, allowing individuals who receive the complete 446 homologous ChAd regimen to obtain better protection through vaccination with vaccines that 447 use different technologies, particularly those based on mRNA ^{16,40}. Nevertheless, the 448 discussion regarding the continued efficacy of the ChAd viral vector in these individuals 449 compared to other antigen vaccine formulations is crucial.

450 Heterologous mRNA vaccination regimens, especially those following the ChAd 451 vaccine, demonstrate similarity to the second and third mRNA homologous and heterologous 452 vaccinations. This can be advantageous for a vaccination regimen that is initiated by a VV 453 vaccine and boosted by mRNA vaccines, potentially mitigating the impact of antibodies 454 directed against the viral vector. However, the use of BNT as a third dose after two ChAd 455 doses is mainly associated with antiviral and interferon responses as well as neutrophils. 456 Additionally, as the samples were limited to the first day after vaccination in this condition, 457 we could not assess the impact of these responses on the adaptive immune system.

458 The Covilo®/BBIBP vaccine is an inactivated virus vaccine formulated with alum 459 adjuvant and evaluated in clinical trials with a homologous two-dose regimen(Wang et al., 460 2020; Al Kaabi et al., 2021; Zhang et al., 2022). The regimen of three homologous doses of 461 BBIBP, specifically when given on days 7, 14, and 28, seems to present a limited 462 immunological profile owing to the nature of the immune response to inactivated viruses⁴³. In 463 a study assessing the effectiveness of two doses of an inactivated influenza vaccine, 464 employing a similar strategy to the development of the BBIBP vaccine, significant changes 465 in gene expression were not observed one week after the second dose. Additionally, no 466 considerable antibody titers were recorded, corroborating the BBIBP vaccine data⁴⁴. 467 However, in another BBIBP vaccine study, this limited immunological profile was not 468 observed, in which a second boost induced more robust humoral and cellular immune responses detected after two weeks⁴⁵. Despite the limited data regarding the efficacy of a third 469 470 dose, it is evident that employing a homologous vaccination strategy with three doses of the 471 inactivated BBIBP vaccine may offer limited immunological benefits. Nevertheless, the third 472 dose demonstrated significant efficacy against the disease ¹⁵. It is important to emphasize the 473 need to evaluate the immune transcriptome after the first two doses in samples from infected 474 patients who have received two or three vaccinations⁴². Furthermore, investigating the early

stages of vaccination, regardless of the number of doses administered, could provide valuableinsights into identifying the genes linked to the innate immune response.

477 The Zifivax®/ZF2001 vaccine was not initially evaluated at the onset of the pandemic 478 when the population had not yet been vaccinated. Instead, it was assessed as a booster dose in individuals who had previously received two doses of the BBIBP vaccine ¹⁵. As expected, in 479 480 a heterologous regimen, vaccination resulted in a distinct gene expression profile when compared to the homologous vaccine ¹¹. These findings suggest that immunological memory 481 plays a pivotal role in the first-week post-vaccination, and antibodies generated by the 482 483 inactivated vaccine recognize, opsonize, and trigger a response to the ZF2001 vaccine protein 484 through the classical pathway of the complement system. Additionally, the original study 485 revealed a significantly higher antibody titer than the homologous regimen, supporting the 486 importance of heterologous vaccination ¹⁵.

487 Importantly, the findings demonstrate the significant contribution of complete vaccination 488 regimens compared to natural infection and incomplete vaccination. Considering that infected 489 patients with incomplete vaccination were hospitalized 10-11 days after vaccination with a 490 single dose of BNT, infection must have occurred some days before hospitalization, and we 491 anticipated that vaccination would not have protected these patients. In the PCA, individuals 492 with prior-vaccination overlapped between the infected cluster and the vaccination cluster C2, 493 which encompassed homologous vaccinations for both convalescent and non-convalescent 494 individuals, along with healthy-vaccinated individuals (Fig. 3A). This overlapping was 495 notable among individuals who were infected after a complete vaccination regimen with BNT. 496 Conversely, an incomplete vaccination regimen was associated with infection, suggesting a 497 limited protection of vaccination administered right before infection. We found that in 498 infected patients with no prior vaccination or with incomplete vaccination the genes related 499 to innate immune cells and processes were highly activated and persisted for several days, 500 especially IFN1 and IFN2, neutrophils, and APCs. Interestingly, bacterium-directed PRRs 501 (TLR4 and NOD) were also highly expressed in these conditions, suggesting that these 502 patients were also coinfected by bacteria, which is a risk factor for hospitalization⁴⁶.

503 To provide a model of key genes that describe infection and the different types of 504 COVID-19 vaccines, we trained a classification random forest model with 244 genes selected 505 from the PCA. Our model identified the 10 genes that are most important for classification, 506 with high accuracy (91.2%) and sensitivity (ROC AUC of 99.0%), and low OOB ratio (8.6%). 507 The genes that classified infection were associated with transcriptional regulation (GATA3, 508 ZNF3, KMT2A, and ASXL1), antiviral response (SP100), and granzymes (GZMM); vaccine 509 types were marked by ARPP (ITGAM, ACTG1, LGALS3) and T-cell response (STAT5B) 510 (Fig. 4B).

511 In addition, we compare COVID-19 vaccines with other vaccines targeting different 512 pathogens, as outlined in the Vax MSigDB dataset (Fig. 5C). This comparison is crucial for 513 understanding how new-generation vaccines, such as mRNA-based and viral-vectored 514 vaccines, relate to classical and consolidated vaccine technologies. Given the pivotal role of 515 the innate immune response in the early stages of both vaccination and infection, the 516 overlapping genes identified likely contribute to the innate immune system ⁴⁷. In particular, 517 bias in FCER1G towards non-COVID-19 vaccines shows a predominance of Th2 response. 518 presumably due to the widespread use of alum adjuvants, a known Th2 response activator that 519 is used in the formulation of BBIBP and ZF2001⁴⁸. This comparison was notable with 520 influenza IN vaccines and LA vaccines against yellow fever and smallpox, which share 521 common DEGs with COVID-19 vaccines in the initial weeks, especially those related to the

522 innate immune system. Additionally, LA vaccines serve as a valuable reference for a robust 523 immune response, mimicking the wild-type virus infection. The observed overlap of LA 524 vaccines with COVID-19 vaccination conditions adds an intriguing dimension to our findings. 525 The diversity in the immunome in vaccines sharing the same technology may be attributed to 526 the specific and varied nature of the adaptive immune system and other technical limitations 527 of the MSigDB Vax dataset. It primarily relies on transcriptomic data from microarrays, which 528 predates the widespread adoption of high-throughput RNA sequencing. In addition, this 529 dataset lacked gene expression fold-change values, highlighting a constraint in our analysis.

530 Although this study provides valuable insights, there are notable limitations regarding 531 the datasets and transcriptomic analyses utilized. Specifically, the use of only bulk RNA-seq 532 data restricts our understanding of the dynamic and heterogeneous behavior of individual 533 immune cells. Furthermore, collecting vaccination and infection samples at different time 534 points presents a limitation in describing the chronological dynamics of the immune response. 535 Specifically, this difference restricts the characterization of the adaptive immune response in 536 vaccination, predominantly assessed within a one-week period. There are additional 537 challenges in analyzing third-dose vaccinations with BNT, MO, and ChAd, which were 538 assessed on the first-day post vaccination, primarily constraining the analysis to the innate and 539 complement immune systems. These restrictions remain significant despite their 540 interconnectedness with the adaptive immune responses elicited by previous doses. In 541 addition, the analysis of BBIBP and ZF2001 vaccines is restricted by the limited time points 542 on the days during the first week, crucial for the innate immune response, and also did not 543 allow us to compare with the preceding doses. Moreover, the observed gene expression pattern 544 was in agreement with the immunological finding of a study, but was contradictory to 545 another(Aydillo et al., 2022; Ying Chen et al., 2023). Exploring how different vaccine 546 technologies contribute to protecting infected vaccinated individuals, as observed in BNT-547 vaccinated individuals, would provide further insight.

548 To improve analysis and interpretation by incorporating supplementary data sources, 549 such as antibody titers, neutralizing antibodies, T cell counts, and clinical trial data, would 550 greatly enhance our understanding. Although sex, age, and VOCs data were present, we did 551 not adjust the contribution of these variables to the immunological signatures described. 552 Adopting a multidimensional approach that integrates various datasets and immunological 553 methodologies would offer a more comprehensive understanding of the immunological 554 landscape after vaccination.

555 **3. Methods**

556 Data curation and processing

557 The selected datasets were first curated using available metadata from Gene Expression 558 Omnibus (GEO) and supplemented with information obtained from pertinent publications 559 (Fig. S1-3, Table 1). We included studies related to SARS-CoV-2 immunization that provided 560 detailed and precise methodology, involved convalescent and non-convalescent patients with 561 or without prior vaccination, and used bulk or single-cell RNA-seq PBMC-derived samples. 562 We excluded studies that lacked methodological descriptions or references, especially 563 concerning sample collection timing between doses, involved TCR and BCR repertoire 564 sequencing, included patients with distinct medical conditions such as autoimmune diseases and cancer, or lacked standardized count matrices. The count matrices for each dataset were 565 obtained from the Gene Expression Omnibus (GEO)⁴⁹ and their metadata from the R package 566 567 GEOquery ⁵⁰. To standardize the gene identifiers as HGNC symbols, we used the R package biomaRT ⁵¹. For reprocessing of reads in the GSE206023 study, FASTQ files were 568 569 downloaded directly from GEO under the accession number GSE206023. The details of the 570 dataset and its accession numbers can be found in Supplementary Table ST1. The 571 average number of reads per sample was approximately 36 million after trimming, which can 572 also be found in the supplementary material. Quality control of raw and trimmed reads was 573 performed using FastQC v.0.11.8 (Andrews, 2010). Trimming of the adapter content and 574 quality trimming was performed using Trimmomatics v0.36, with the following settings: 575 LEADING 20 TRAILING 20 SLIDINGWINDOW 4:25 MINLEN 31, and the Kallisto index 576 was built with reference transcriptome GRCh38 (Ensembl) with a k-mer length of 31 using 577 the Kallisto v.46.0 programs, and the abundance of the transcripts was quantified using the Kallisto pseudo-alignment, which provides estimates of transcript levels ^{17,52,53}. Subsequently, 578 579 we used the tximport R package to summarize count estimates at the gene level ⁵⁴.

580 Differential gene expression analysis

581 Differential gene expression analysis was performed independently for each dataset using the

- 582 R package DESeq2 ⁵⁵. We used the Wald test with the interaction terms vaccine and time 583 point. DEGs were filtered based on the Benjamini-Hochberg adjusted p-values (padj < 0.05).
- 584 We classified up and downregulated genes by $\log 2$ fold change (-1 < L2FC > 1, respectively).

585 Gene set enrichment analysis

586 The ontology of biological processes within the immune system ["immune system process" (GO:0002376)] was obtained from the GO.db package ⁵⁶. To facilitate subsequent analyses, 587 588 biological processes associated with the immune system were categorized into three distinct 589 groups: "Immune system," "Immune subsystem," and, when related to specific cells, classified 590 under the "Immune cell" category. The VAX MSigDB database was obtained via the MSigDB 591 portal and manually annotated with the available information on the dataset. We used only 592 peripheral blood mononuclear cell-derived samples. The enrichment analysis of DESeq2 593 results was conducted with ImmuneGO using the Enricher and Clusterprofiler packages for 594 over-representation analysis (ORA) and gene set enrichment analysis (GSEA) ⁵⁷. Heatmaps 595 package in visualized using the ComplexHeatmap R and Morpheus were (https://software.broadinstitute.org/morpheus) ^{58,59}. 596

597 Principal component analysis and machine learning classification

598 PCA was performed using L2FC values of immune-related DEGs, through the factoextra R 599 package ⁶⁰. For cluster analysis, we used the k-nearest neighbors (KNN) algorithm. To 600 optimize the efficiency of our random forest classification, we initially filtered genes based 601 on their cosine squared values in the first two principal components, setting a threshold above 602 0.5. We then constructed our random forest classifier by leveraging the tidymodels package 603 (Kuhn & Wickam, 2020). Our dataset was partitioned into training (70%) and testing (30%) 604 sets, with stratification for the "type" variable and upsampling to address class imbalance. 605 Employing cross-validation, we fine-tuned the model's hyperparameters using a grid search 606 method within the tidymodels framework. Performance evaluation metrics, including AUC, 607 ROC, OOB, and accuracy, guided the optimization of hyperparameters, including mtry and 608 min n. Finally, the optimized random forest model was trained on the entire training dataset 609 and subsequently assessed on the testing dataset to evaluate its predictive performance.

610 Data and code availability

Raw and processed data, as well as codes used are available on the project Github repository(https://github.com/wapsyed/covidvax atlas).

613 Author Contributions:

- 614 WAPS, DLMF Conceptualization and manuscript writing;
- 615 LV, AL, NC, EC, JSD Manuscript contributions;
- 616 WAPS, DLMF, SZP Data analysis;
- 617 OC, HIN, LFS, ISF, GW, RDC, NOSC, HDD, HDO, ECS, JEK Review and editing;
- 618 GCM, OCM, HIN Supervision, editing, and approval of the final version.
- **Funding**: We thank the São Paulo Research Foundation (FAPESP grants 2019/14526-0 and
- 620 2020/05146-7 to GCM; 2018/18886-9 to OCM; 2023/07806-2 to ISF; 2020/16246-2 and
- 621 2023/13356-0 to DLMF; 2019/01255-9 and 2021/03684-4 to RDC) for financial support. We
- 622 acknowledge the National Council for Scientific and Technological Development (CNPq)
- 623 Brazil (grants: 309482/2022-4 to OCM and 102430/2022-5 to LFS).
- 624 Conflicts of Interest: The authors declare that they have no competing interests.

625 Tables

				Vaccinatio	n			
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnarty	НО	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		НО	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		НО	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	16
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		BI	10, 26, 51	2x BNT + 1x I	RNA + I	No	GSE201530	13
		BI	10, 26, 51	1x BNT (10 dpi) + 1x I	RNA + I	No	GSE189039	5
		AI	10	1x BNT + 1x I + 1x BNT	RNA + I	No	GSE189039	2
		AI	0, 10, 26, 51	1x I + RNA + 1x I	I + RNA + I	No	GSE201530	1

AZD1222 (ChAd)	Covishield, Vaxzebria	НО	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750, GSE201533	12
		НО	0, 3, 6	1x ChAd	VV	No	GSE199750, GSE201533	53
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	17
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
mRNA- 1273 (MO)	Spikevax	HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
BBIBP- CorV (BBIBP)	Covilo	НО	0, 7, 14, 28	3 (3rd dose)	IN	Alum	GSE206023	6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose)	SU	Alum	GSE206023	6

			Infection			
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

- 628 Table 1. Vaccines and infection conditions selected in this study. Legend: HO: Homologous;
- 629 HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; RNA: mRNA; VV:
- 630 Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A:
- 631 Asymptomatic.

632 Figures



Fig. 1. Methods and description of datasets and study population. (A) We manually curated
the GEO datasets and performed differential gene expression analysis. Finally, genes from
immune system biological process (GO:) and the VAX collection from MSigDB were used
in GSEA and ORA, and individual gene expression analysis was analyzed across the studied
conditions. Created with Biorender. Number of participants (B) and samples (C) were
categorized by vaccine and infection conditions. Legend: BBIBP: BBIBP-CORV; BNT:
BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.



Fig. 2. A. Differentially expressed genes (DEGs) were categorized as up- (left panel) and 643 644 down-regulated (right panel) with the absolute and relative number of genes. The conditions 645 were then plotted with the total number of genes and immune genes. Labels correspond to the 646 total number of immune genes and the percentage over total DEGs. B. Shared DEGs between 647 infection and vaccination. The upper-left cluster include individuals infected for the first time, 648 and the bottom-right cluster comprise the first week of vaccination by RNA, VV, and SU 649 vaccines. C. Twenty most shared immune-related genes. Legend: BBIBP: BBIBP-CORV; 650 BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN: 651 Inactivated; RNA: mRNA vaccines; SU: Subunit; VV: Viral vector. B. Shared DEGs in 652 vaccination and infection.



Fig. 3. Principal component analysis. A. Two principal components were employed to plot all
conditions, capturing 86.2% of the total variance. K-nearest neighbors (KNN) clustering
identified three distinct clusters. Cluster 1 (C1) includes infected patients and overlaps with

657 Cluster 2 (C2). C2 is predominantly characterized by vaccination in healthy individuals, 658 encompassing convalescent patients and non-convalescent individuals. Cluster 3 (C3) 659 comprises the initial three days post-vaccination with mRNA vaccines and ChAd. B. The 660 loading plot displays cos2 values for the top 20 genes in PC1 and PC2. The top 20 genes contributing to PC1 (C) and PC2 (D), along with the corresponding Log2 Fold Change 661 (L2FC). Genes were displayed with correspondent log2-fold change ranging from -2 (blue) to 662 663 2 (red). The left annotation on the heatmap depicts the contribution to different immune 664 processes and cells, with colors corresponding to processes and cells related to the 665 complement system (pink), the innate (greens) and adaptive immune systems (purples), and 666 general processes and cells (leukocytes, black). Legend: BBIBP: BBIBP-CORV; BNT: 667 BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.



Fig. 4. DEGs with cos2 > 0.5 were used to train a random forest model to predict the types of
 vaccines and infection, and the ten most important genes were selected (A). The final model
 was selected after an iterative process of hyperparameter tuning. The best model was defined

- 672 with 2000 trees in the forest, where mtry was set to 6 and min_n to 6. The most important
- 673 genes were used to plot the log2-fold change (L2FC) (B). C. Gene set enrichment analysis of
- 674 COVID-19 vaccines and infection. Major immunological gene sets were enriched with GSEA.
- 675 Normalized enrichment scores (NES) for enriched gene sets, with circle size corresponding
- 676 to -log(qvalue). D. Representation of upregulated (red) and downregulated (blue) genes in
- 677 COVID-19 conditions associated with various immune biological processes. Visualization IN
- 678 stacked hierarchical layout was generated using Cytoscape ⁶¹. Node size is determined by
- degree centrality, and node colors are determined by type and infection status. Illustration
 made in **BioRender.** Legend: BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1;
- 681 MO: mRNA-1273; I: Infected; V: Vaccinated.



Fig. 5. Gene-level comparison of COVID-19 vaccines and the MSigDB Vax collection.
Overlapping immune-related (A) and other (B) genes between conditions. C. Genes with the
most sharing between COVID-19 vaccination and other vaccines. Visualization in stacked

hierarchical layout was generated using Cytoscape ⁶¹. C. All immune-related genes shared at 686 687 least once between conditions. D. Genes included in the first cluster (see complete heatmap in Fig. S9) were set with L2FC as 1 (upregulated) and -1 (downregulated). These genes were 688 689 annotated by their corresponding contribution to subprocesses and cells among the innate, 690 adaptive and complement immune systems (left). E. Over-representation analysis of vaccines against COVID-19 and other pathogens with immune cells and processes. Legend: BBIBP: 691 BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: 692 693 Vaccinated.

695 Supplementary Material

696 Supplementary Figures



698 Fig. S1. Data curation. Datasets were obtained from NCBI BioProject and curated. All

datasets, including the selected and non-selected, were classified by vaccine technology and

vaccination regimen, and by sample source.





Fig. S2. Description of the selected datasets. The datasets include healthy vaccinees without
 prior infection, infected patients without vaccination, and patients with prior full or
 incomplete vaccination. Sample collection timelines are shown as black lines, with red lines
 indicating the first sample collection during hospitalization and gray lines representing events
 without sample collection. Days post-infection or vaccination are depicted, with blue lines

708 representing hospitalization periods and purple lines indicating dexamethasone treatment.



Fig. S3. DEGs were categorized as up- (A) and down-regulated (B) with the absolute and relative number of genes, and grouped based on infection (red) and vaccination (blue)

- 712 conditions. The conditions were then plotted with the relative number of genes corresponding
- 713 to their roles in essential biological processes, namely immune system, cellular processes,
- metabolism, and regulation of biological processes, respectively. Shapes correspond to type,
 colors to disease or infection, and size to total number of DEGs. I: Infection; IN: Inactivated;
- 716 RNA: mRNA vaccines; SU: Subunit; VV: Viral vector.





718 Fig. S4. A. Shared non-immune-related DEGs between infection and vaccination. B. Twenty

719 most shared immune-related genes. BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd:

720 ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN: Inactivated; RNA: mRNA

721 vaccines; SU: Subunit; VV: Viral vector.



- 723 Fig. S5. Genes related to complement system, antimicrobial response, and innate immune
- system processes and cells. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU: Subunit;
- 725 VV: Viral vector.



Fig. S6. Genes related to humoral adaptive immune system, including B cell processes and
immunoglobulin-mediated response. I: Infection; IN: Inactivated; RNA: mRNA vaccines;
SU: Subunit; VV: Viral vector.



730

731 Fig. S7. Genes related to the cellular adaptive immune system, including cellular response

and T- and T helper cell processes. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU:
Subunit; VV: Viral vector.







737

- **Fig. S9.** Gene expression in vaccination against COVID-19 and other pathogens. I: Infection;
- 739 IN: Inactivated; RNA: mRNA vaccines; SU: Subunit; VV: Viral vector; CONJ: Conjugated;
- 740 LA: Live-attenuated; VLP: Virus-like particle.

742 References

743 744	1.	Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. <i>The Lancet</i> 395 , 470–473 (2020).
745 746	2.	Chung, H. W. <i>et al.</i> Effects of government policies on the spread of COVID-19 worldwide. <i>Sci Rep</i> 11 , 20495 (2021).
747 748 749	3.	Xia, S., Wang, L., Zhu, Y., Lu, L. & Jiang, S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. <i>Signal Transduct Target Ther</i> 7 , 241 (2022).
750 751	4.	Watson, O. J. <i>et al.</i> Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. <i>Lancet Infect Dis</i> 22 , 1293–1302 (2022).
752 753	5.	Li, Y. <i>et al.</i> A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. <i>ACS Cent Sci</i> 7 , 512–533 (2021).
754 755 756 757	6.	World Health Organization (WHO). Status of COVID-19 Vaccines within WHOEUL/PQevaluationprocess.https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08AUgust2023.pdf (2023).
758 759	7.	Mathieu, E. <i>et al.</i> A global database of COVID-19 vaccinations. <i>Nat Hum Behav</i> 5 , 947–953 (2021).
760 761	8.	Atmar, R. L. <i>et al.</i> Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> 386 , 1046–1057 (2022).
762 763 764	9.	Vasconcelos, Z. S. <i>et al.</i> Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. <i>Rev Soc Bras Med Trop</i> 56 , (2023).
765 766	10.	Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. <i>Nat Rev Immunol</i> 21 , 83–100 (2021).
767 768	11.	Costa Clemens, S. A. <i>et al.</i> Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-

- 769 19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind,
 770 randomised study. *The Lancet* **399**, 521–529 (2022).
- 12. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2
 Vaccine. *New England Journal of Medicine* **384**, 403–416 (2021).
- 13. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
 controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99–111
 (2021).
- 14. Dai, L. *et al.* Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine
 ZF2001 in Adults. *New England Journal of Medicine* **386**, 2097–2111 (2022).
- 779 15. Al Kaabi, N. *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on
 780 Symptomatic COVID-19 Infection in Adults. *JAMA* 326, 35 (2021).
- Wu, N. *et al.* Long-term effectiveness of COVID-19 vaccines against infections,
 hospitalisations, and mortality in adults: findings from a rapid living systematic
 evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med* 11, 439–452 (2023).
- 785 17. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic
 786 RNA-seq quantification. *Nat Biotechnol* **34**, 525–527 (2016).
- 18. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based
 genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol* 37, 907–915 (2019).
- Romero Starke, K. *et al.* The isolated effect of age on the risk of COVID-19
 severe outcomes: a systematic review with meta-analysis. *BMJ Glob Health* 6,
 e006434 (2021).
- 793 20. Knabl, L. *et al.* BNT162b2 vaccination enhances interferon-JAK-STAT794 regulated antiviral programs in COVID-19 patients infected with the SARS795 CoV-2 Beta variant. *Communications Medicine* 2, 17 (2022).

- 796 21. Haseeb, Pirzada, Ain & Choi. Wnt Signaling in the Regulation of Immune Cell
 797 and Cancer Therapeutics. *Cells* 8, 1380 (2019).
- Xiao, Y., Peperzak, V., Keller, A. M. & Borst, J. CD27 Instructs CD4+ T Cells
 to Provide Help for the Memory CD8+ T Cell Response after Protein
 Immunization. *The Journal of Immunology* **181**, 1071–1082 (2008).
- 801 23. Mohan, T., Zhu, W., Wang, Y. & Wang, B.-Z. Applications of chemokines as
 802 adjuvants for vaccine immunotherapy. *Immunobiology* 223, 477–485 (2024).
- Adewoye, A. B. *et al.* Human CCL3L1 copy number variation, gene expression,
 and the role of the CCL3L1-CCR5 axis in lung function. *Wellcome Open Res*3, 13 (2024).
- 806 25. Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and 807 immunopathology of COVID-19. *Science (1979)* **375**, 1122–1127 (2022).
- Afzali, B., Noris, M., Lambrecht, B. N. & Kemper, C. The state of complement
 in COVID-19. *Nat Rev Immunol* 22, 77–84 (2022).
- Almuqrin, A. *et al.* SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human
 cell lines reveals low levels of viral backbone gene transcription alongside very
 high levels of SARS-CoV-2 S glycoprotein gene transcription. *Genome Med*13, 43 (2021).
- 814 28. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics*815 27, 1739–1740 (2011).
- BiazGranados, C. A. *et al.* Efficacy of High-Dose versus Standard-Dose
 Influenza Vaccine in Older Adults. *New England Journal of Medicine* **371**, 635–
 645 (2014).
- 819 30. Piras-Douce, F. *et al.* Next generation live-attenuated yellow fever vaccine
 820 candidate: Safety and immuno-efficacy in small animal models. *Vaccine* 39,
 821 1846–1856 (2021).
- 822 31. Behrens, R. H. & Patel, V. Avoiding shoulder injury from intramuscular
 823 vaccines. *The Lancet* **397**, 471 (2021).

824 32. Salgado-Albarrán, M. et al. Comparative transcriptome analysis reveals key 825 epigenetic targets in SARS-CoV-2 infection. NPJ Syst Biol Appl 7, 21 (2021). 826 33. Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology 827 and cellular targets. Nature 595, 107–113 (2021). 828 34. Pereira, N. L. et al. COVID-19: Understanding Inter-Individual Variability and 829 Implications for Precision Medicine. Mayo Clin Proc 96, 446-463 (2021). 830 35. Liang, F. et al. Efficient Targeting and Activation of Antigen-Presenting Cells 831 In Vivo after Modified mRNA Vaccine Administration in Rhesus Macagues. 832 Molecular Therapy 25, 2635–2647 (2017). 833 Karikó, K. et al. Incorporation of Pseudouridine Into mRNA Yields Superior 36. 834 Nonimmunogenic Vector With Increased Translational Capacity and Biological 835 Stability. Molecular Therapy 16, 1833–1840 (2008). 836 37. Xia, X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and 837 Moderna mRNA Vaccines. Vaccines (Basel) 9, 734 (2021). 838 38. Dicks, M. D. J. et al. A Novel Chimpanzee Adenovirus Vector with Low Human 839 Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS One 7, e40385 (2012). 840 841 39. Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E. & Blasi, M. The use of viral 842 vectors in vaccine development. NPJ Vaccines 7, 75 (2022). 843 40. Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous 844 ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic 845 Covid-19 infection in Sweden: A nationwide cohort study. The Lancet Regional 846 Health - Europe 11, 100249 (2021). 847 41. Wang, H. et al. Development of an Inactivated Vaccine Candidate, BBIBP-848 CorV, with Potent Protection against SARS-CoV-2. Cell 182, 713-721.e9 849 (2020).

42. Zhang, Y. *et al.* Real-world study of the effectiveness of BBIBP-CorV
(Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. *BMC Public Health*22, 1584 (2022).

43. Sanders, B., Koldijk, M. & Schuitemaker, H. Inactivated Viral Vaccines. in *Vaccine Analysis: Strategies, Principles, and Control* 45–80 (Springer Berlin
Heidelberg, 2015). doi:10.1007/978-3-662-45024-6 2.

Aydillo, T. *et al.* Transcriptome signatures preceding the induction of anti-stalk
antibodies elicited after universal influenza vaccination. *NPJ Vaccines* 7, 160
(2022).

859 45. Chen, Y. *et al.* Immunity Induced by Inactivated SARS-CoV-2 Vaccine:
860 Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort.
861 *Pathogens* **12**, 1254 (2023).

862 46. Patton, M. J. *et al.* COVID-19 bacteremic co-infection is a major risk factor for
863 mortality, ICU admission, and mechanical ventilation. *Crit Care* 27, 34 (2023).

864 47. Sette, A. & Crotty, S. Immunological memory to <scp>SARS-CoV</scp> -2
865 infection and <scp>COVID</scp> -19 vaccines. *Immunol Rev* 310, 27–46
866 (2022).

867 48. Pulendran, B., S. Arunachalam, P. & O'Hagan, D. T. Emerging concepts in the
868 science of vaccine adjuvants. *Nat Rev Drug Discov* 20, 454–475 (2024).

869 49. Edgar, R. Gene Expression Omnibus: NCBI gene expression and hybridization
870 array data repository. *Nucleic Acids Res* **30**, 207–210 (2024).

50. Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression
Omnibus (GEO) and BioConductor. *Bioinformatics* 23, 1846–1847 (2007).

51. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological
databases and microarray data analysis. *Bioinformatics* 21, 3439–3440 (2024).

875 52. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for
876 Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

53. Hunt, S. E. *et al.* Ensembl variation resources. *Database* **2018**, (2018).

- Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq:
 transcript-level estimates improve gene-level inferences. *F1000Res* 4, 1521
 (2016).
- 55. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
 dispersion for RNA-seq data with DESeq2. *Genome Biol* 15, 550 (2014).
- 883 56. Carlson, M. GO.db: A set of annotation maps describing the entire Gene
 884 Ontology. *R package version 3.8.2.*
- 885 57. Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting
 886 omics data. *The Innovation* 2, 100141 (2021).
- 58. Gu, Z. Complex heatmap visualization. *iMeta* **1**, (2022).
- Solution Sector Secto
- 891 60. Lê, S., Josse, J. & Husson, F. FactoMineR : An *R* Package for Multivariate
 892 Analysis. *J Stat Softw* 25, (2008).
- 893 61. Shannon, P. *et al.* Cytoscape: A Software Environment for Integrated Models
 894 of Biomolecular Interaction Networks. *Genome Res* 13, 2498–2504 (2003).



С

B



Total

Immune

	Upreg	gulated			Downregulat	ed	
BBIBP (V3, D07)	3 (7.9% of 38)			4 (30.8% of 13)			
BBIBP (V3, D14) -	35 (13.4% of 261)			4 (26.7% of 15)			
BBIBP (V3, D28) -	23 (9.1% of 254)			12 (75% of 16)			
BNT (V1, D6) —	2 (100% of 2)						
BNT (V2, D1) —	103 (30.7% of 336)			7 (3.8% of 186)			
BNT (V3, D1) -	127 (31% of 410)			5 (5.6% of 89)			
BNT-I (D1)	120 (14.9% of 804)			38 (17.8% of 214)			
BNT-I (D10, mild)		326 (19.5% of 1672)				305 (12.4% of 2	2455)
BNT-I (D10. severe) -		377 (17% of 2218)				269 (12.8% of 2094)	,
BNT-I (D26, mild) —	182 (16.6% of 10	096)			170 (13.2% of 1288)	, , , , , , , , , , , , , , , , , , ,	
BNT-I (D26, severe)	47 (14.4% of 326)	-,		31 (14.2% of 219)	- (- · · · · · · · · · · · · · · · · ·		
BNT-I (D3) —	100 (18% of 556)			6 (9.4% of 64)			
BNT-I (D4)	17 (16.8% of 101)			5 (12.8% of 39)			
NT-I-BNT (D51 mild) -	25 (21.9% of 114)			40 (18.5% of 216)			
-I-BNT (D51 severe) —	7 (14 6% of 48)			7 (12.5% of 56)			
BNT-MO(V3 D1) =	158 (23.6% of 670)			28 (12% of 234)			
ChAd(V1 D3) =	96 (30 7% of 313)			37 (12 2% of 304)			
ChAd(V1, D0) - ChAd(V1, D0)	66 (48 2% of 137)			2 (25% of 8)			
ChAd(V1, D0)	27 (13 6% of 199)			9 (16 1% of 56)			
ChAd(V2,D1) =	114 (25 2% of 452)			27 (10.8% of 249)			
ChAd(V2, D1)	9 (5.3% of 169)			2(10.5% of 19)			
ChAd(V2, D0)	0 (0.070 01 100)			1 (20% of 5)			
$ChAd_BNT(V2, D3) =$	111 (21 1% of 589)			35(13.9% of 252)			
ChAd-BNT(V2, D3)	17 (6.2% of 274)			97 (20.9% of 464)			
ChAd-BNT(V2, D1) =	104 (23.9% of 812)			44 (27% of 163)			
L(D10 modorato) =	194 (23.9 % 01012)	280(16.6% of 1688)		44 (27 % 01 103)	100 (15 0% of 1240)		
I(D10, moderate)		208 (13 0°/ of 21/2)			001 (10 0	8% of 1678)	
I (D10, Severe)	171 (15 0% of 10	76)		120 (16 0	201 (13.0	5/6 01 1070)	
I(D20, III)	171 (15.9% 01107	237(13.10/ of 1812)		139 (18.5	() () () () () () () () () () () () () (80(11.5% of 1022)	
I(D20, Severe)	9(25.7% of 35)	237 (13.1 /8 01 1012)		3(23.1% of 12)	2	00 (14.5 % 01 1952)	
I(D51, III)	3 (23.7 /0 01 33)	10(10.2% of 1566)					
	1(22.2% of 2)	0 (19.2 % 01 1300)		00 (11.5% 01 592)		
	1 (33.3% 013)			10(07,19) of 05)			
				1.3(37.1% 01.33)			
ZF2001 (V3, D07) =	39 (16.2% 07 241)			22 (12.3% OT 1/9)			
ZF2001 (V3, D14) =	21 (9.7% 0T 216)			7 (16.7% OT 42)			
ZF2001 (V3, D28) —	/ (11.3% OT 62)			6 (12.2% Of 49)			
	0 1000 2000) 3000	4000	0 1000	2000	3000	4000



BNT-I (D10, severe) BNT-I (D26, severe) ChAd (V1, D10, I-I (D11), severe) ChAd (V1, D6) BNT-I (D51, minder) BNT-I (D51, minder) BNT-I (D51, severe) ChAd (V1, D6) I-BNT-I (D51, severe) ChAd (V1, D6) I-BNT-I (D21, severe) ChAd (V1, D6) I-I (D11) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D14) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D14) I-I (D1) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D14) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) ChAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) CHAd (V2, D3) BBIBP (V3, D28) BNT-I (D21, severe) CHAd (V2, D3) BNT-I (D21, severe) CHAC (V2, D3) BNT-I (D21, severe) CHAC (V2, D1)





Ε



Α																																					
															In	۱m	าน	ne	e-r	el	at	ec		ЭЕ	G	S											I
															_																						
						10							~ 1							-	-	_						-		-							
WEIVAX (D5-7))			60	57	42	36	32	29	23	23	26	24	30	32	29	23	19	9	5	8	3	4	1	1	4	1	2	1	2							
STAMARIL (D7))			50	42	37	40	34	35	30	29	28	28	26	28	28	1/	8	10	6	5	2	2	4	2	3		1	1	1		0	0				
STAMARIL (D10))			38	35	31	33	30	32	25	21	25	26	17	15	19	10	5	11	2	2	2	1	5	3			1	1			2	2				
STAMARIL (D3))			37	32	25	30	28	30	23	25	21	22	20	19	18	11	2	5	5	1			2	1	2		1	1	1							
HPV-VLP (M2))			28	30	22	20	14	11	16	14	11	8	22	20	18	11	14	11	11	6	11	6	2	1	1	3	2			2	1	1				
FLUMIST (D3))			32	28	21	18	16	12	11	14	11	9	23	20	23	13	9	1	7	4	8	4			2	1										
IIV-1 GAG-POL NEF (D3))			25	26	21	24	23	25	20	17	19	20	10	9	11	4	3	6	2	1	2		1	1	1	1	1	1								
MVA85A (D2))			18	17	13	21	20	19	19	18	17	16	9	10	10	2	2	10	3	2	1		2	1		2		1		1				1		
FLUARIX FLUVIRIN (D3))			23	17	14	5	5	1	1	5	1		20	18	8	15	9		10	2	4	2				1					1		1			
PANDEMRIX (D7))			15	16	13	14	14	14	13	12	13	11	8	4	9	4	2	2		1			1	1				1								
YF17D (D3))			10	14	12	12	13	13	13	9	12	12	5	5	5	1	1	3					2	1				1								
WETVAX (D2-4))			11	13	11	9	7	6	7	7	8	7	5	4	10	3	2	6	3	7			1				1									
/S F TULARENSIS (H48))			11	14	11	9	5	4	4	3	4	4	14	9	9	6	4	4	5	3	1	2			1	1										
VS F TULARENSIS (H18))			11	14	11	9	5	4	4	3	4	4	14	9	9	6	4	4	5	3	1	2			1	1										
S F TULARENSIS (H336))			11	14	11	9	5	4	4	3	4	4	14	9	9	6	4	4	5	3	1	2			1	1										
S F TULARENSIS (H192))			11	14	11	8	5	4	4	3	4	4	13	9	9	6	4	4	5	3	1	2			1	1										
MENACTRA (D3))			3	7	5	1		1	3	4	1	1	3	4	5	2	1	3	3	1	2					3	2			1						
PANDEMRIX (D1))			2	4	2	5	4	3	2	1	3	4	2	1	4	1				1		1			1											
INFLUENZA (D1))					1	1	2	1	1	1	1	1					1							3												
YF VAX (ANY))						1	1	1			1	1		1																						
ZOSTAVAX (D1))																																				
	microbe type	type	week	BNT-I (D10, mild)	BNT-I (D10, severe)	I (D10, moderate)	ChAd-BNT (V3, D1)	BNT-MO (V3, D1)	ChAd (V2, D1)	ChAd-BNT (V2, D3)	ChAd (V1, D3)	BNT (V3, D1)	BNT (V2, D1)	I (D10, severe)	I (D26, severe)	I (D51, severe)	BNT-I (D26, mild)	I (D26, moderate)	ChAd-BNT (V2, D7)	ZF2001 (V3, D07)	BNT-I (D3)	BNT-I (D1)	BNT-I (D26, severe)	ChAd (V1, D7)	ChAd (V1, D6)	BNT-I-BNT (D51, mild)	ZF2001 (V3, D28)	ZF2001 (V3, D14)	BNT (V1, D6)	I-I (D1)	ChAd (V2, D3)	BNT-I (D4)	I (D51, moderate)	NT-I-BNT (D51, severe)	BBIBP (V3, D14)	BBIBP (V3, D28)	ChAd (V2, D7)

B



Shared 60

40

20

0





medRxiv preprint doi: https://doi.org/10.1101/2024.05.22 24307755; this version posted June 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



				Vaccination				
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnarty	НО	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		НО	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		НО	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	16
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		BI	10, 26, 51	2x BNT + 1x I	RNA + I	No	GSE201530	13
		BI	10, 26, 51	1x BNT (10 dpi) + 1x I	RNA + I	No	GSE189039	5
		AI	10	1x BNT + 1x I + 1x BNT	RNA + I	No	GSE189039	2
		AI	0, 10, 26, 51	1x I + RNA + 1x I	I + RNA + I	No	GSE201530	1
AZD1222 (ChAd)	Covishield, Vaxzebria	HO	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750,	12
							GSE201533	
		HO	0, 3, 6	1x ChAd	VV	No	GSE199750,	53
							GSE201533	
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	17
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5

mRNA-1273 (MO)	Spikevax	HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
BBIBP-CorV (BBIBP)	Covilo	НО	0, 7, 14, 28	3 (3rd dose)	IN	Alum	GSE206023	6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose)	SU	Alum	GSE206023	6

			Infection			
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

Table 1. Vaccines and infection conditions selected in this study. Legend: HO: Homologous; HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; VV: Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A: Asymptomatic.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.22.24307755; this version posted June 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.